Sartorius Stedim Biotech Stock Annual Yield
| DIM Stock | EUR 168.60 0.55 0.33% |
Sartorius Stedim Biotech fundamentals help investors to digest information that contributes to Sartorius Stedim's financial success or failures. It also enables traders to predict the movement of Sartorius Stock. The fundamental analysis module provides a way to measure Sartorius Stedim's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sartorius Stedim stock.
Sartorius |
Sartorius Stedim Biotech Company Annual Yield Analysis
Sartorius Stedim's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Current Sartorius Stedim Annual Yield | 0 % |
Most of Sartorius Stedim's fundamental indicators, such as Annual Yield, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sartorius Stedim Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Sartorius Stedim Biotech has an Annual Yield of 0.0047%. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Instruments & Supplies industry. The annual yield for all France stocks is notably lower than that of the firm.
Sartorius Annual Yield Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sartorius Stedim's direct or indirect competition against its Annual Yield to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sartorius Stedim could also be used in its relative valuation, which is a method of valuing Sartorius Stedim by comparing valuation metrics of similar companies.Sartorius Stedim is currently under evaluation in annual yield category among its peers.
Sartorius Fundamentals
| Return On Equity | 0.41 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 31.28 B | |||
| Shares Outstanding | 92.17 M | |||
| Shares Owned By Insiders | 73.81 % | |||
| Shares Owned By Institutions | 13.83 % | |||
| Price To Earning | 80.53 X | |||
| Price To Book | 13.32 X | |||
| Price To Sales | 8.58 X | |||
| Revenue | 3.49 B | |||
| Gross Profit | 1.83 B | |||
| EBITDA | 1.33 B | |||
| Net Income | 1.13 B | |||
| Cash And Equivalents | 161.7 M | |||
| Cash Per Share | 1.75 X | |||
| Total Debt | 1.02 B | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 26.58 X | |||
| Cash Flow From Operations | 612.3 M | |||
| Earnings Per Share | 9.52 X | |||
| Price To Earnings To Growth | 3.36 X | |||
| Target Price | 412.2 | |||
| Number Of Employees | 11.93 K | |||
| Beta | 0.45 | |||
| Market Capitalization | 28.45 B | |||
| Total Asset | 5.07 B | |||
| Retained Earnings | 462 M | |||
| Working Capital | 122 M | |||
| Current Asset | 439 M | |||
| Current Liabilities | 317 M | |||
| Z Score | 16.2 | |||
| Annual Yield | 0 % | |||
| Five Year Return | 0.57 % | |||
| Net Asset | 5.07 B | |||
| Last Dividend Paid | 1.44 |
About Sartorius Stedim Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sartorius Stedim Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sartorius Stedim using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sartorius Stedim Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Sartorius Stock
Sartorius Stedim financial ratios help investors to determine whether Sartorius Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.